EUVIMED · CrossrefZeitschrift
Cell and Gene Therapy Insights
ISSN 2059-7800 · BioInsights Publishing, Ltd.
Neueste Artikel
Comparative assessment of drug substance frozen storage containers for AAV8 manufacturing
Industry Insights: Base editing nears its first BLA as AAV safety comes under scrutiny
Comparability, bridging studies, and regulatory considerations: making the move to AAV producer cell lines
Reflecting on the evolution of gene therapy from good idea to mundane miracle
AI in cell and gene therapy – a glimpse into the future while facing reality
AI and digital transformation in cell and gene therapy: enabling scalable and predictable biomanufacturing
From feasibility to access: how is cell therapy’s central challenge evolving?
AI-driven LNP design: unlocking non-viral delivery for cell and gene therapy
Industry Insights: Expanding access across the field, from pediatric approvals to the first solid tumor CAR‑T
AI in CGT needs AI-worthy data, not just better models
What CGT can learn from biologics: high‑value AI use cases for manufacturing
Industry Insights: The first CAR-T approval in solid tumors and the FDA recalibrates
The regulatory frontier advancing cell and gene therapy policy in Singapore and beyond
Frozen in time: rethinking cryopreservation as a core process parameter in cell and gene therapy
Event preview of the 6th iPSC Drug Development Summit
Engineering armored CAR‑T cells to overcome the solid tumor microenvironment
A consortium‑driven framework for expanding access to interventional neurosurgical cell therapy for Parkinson's disease
Beyond viral vectors: Hao Wu on non-viral delivery, immune-evasive DNA, and what the field still needs to prove
From shelved to delivered: CGTxchange and the push for improved patient access to cell and gene therapies
The non-viral delivery era has begun, with challenges ahead
Event Summary: ASGCT 2026 Annual Meeting
Don’t shoot the messenger: non‑viral delivery’s real‑world revolution
CERSI‑AT: practical guidance for decentralized manufacturing
Building CAR‑T therapies with GMP‑first thinking
Towards intelligent supply networks: AI‑enabled simulation in the evolution of digital twins for autologous cell therapy manufacturing
Event Preview – Cell & Gene Therapy World Asia
Industrialization of cell therapy manufacturing: from artisanal process to scalable medicine
In vivo CAR-T: toward scalable and programmable immunotherapy
From bottleneck to breakthrough: how downstream process innovation, analytics, and AI are reshaping AAV‑based gene therapy
Beyond the bespoke: could automation hold the key to the CAR‑T accessibility issue?
EUVIMED